@Article{biocell.2021.015899,
AUTHOR = {FUJI YANG, YAN HUANG, YOUWEN TAN, YONGMIN YAN},
TITLE = {Ubiquitin-like posttranslational modifications in NAFLD progression and treatment},
JOURNAL = {BIOCELL},
VOLUME = {46},
YEAR = {2022},
NUMBER = {2},
PAGES = {389--400},
URL = {http://www.techscience.com/biocell/v46n2/45099},
ISSN = {1667-5746},
ABSTRACT = {Nonalcoholic fatty liver disease (NAFLD) is a long-lasting condition that affects the liver, destroying its
function. Liver injury can cause steatosis and inflammation, and further activation of hepatic stellate cells (HSCs)
often leads to the development of nonalcoholic liver fibrosis. The patient with NAFLD is at risk of developing
advanced liver disease and complications, such as liver failure, hepatocellular carcinoma (HCC), and portal
hypertension. Although our understanding of the cellular and molecular mechanisms of NAFLD has greatly improved
in recent years, treatment remains limited. Analysis and characterization of protein posttranslational modifications
(PTMs) could improve our understanding of NAFLD pathology and leading to the development of new and more
effective treatments. In recent years, a number of studies have described how ubiquitin-like (Ubl)-PTMs change
during NAFLD and how treatments targeting specific enzymes mediating these Ubl-PTMs can improve various liver
diseases, particularly in relation to NAFLD and nonalcoholic liver fibrosis. New strategies for evaluating modified
proteomes could provide novel insights into the roles of Ubl-PTMs in NAFLD progression and the therapeutic value
of targeting the proteins involved in these Ubl-PTMs.},
DOI = {10.32604/biocell.2021.015899}
}